Form 4: REGENXBIO Executive Danos Olivier Reports Stock Transactions

Chief Scientific Officer of REGENXBIO, Danos Olivier, reports acquisition and disposal of company stock, including purchases through the Employee Stock Purchase Plan and vesting of restricted stock units.

Summary

• REGENXBIO's Chief Scientific Officer, Danos Olivier, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On June 28, 2024, Danos acquired 1,363 shares of common stock through the Employee Stock Purchase Plan (ESPP) at a price of $9.945 per share.
• On August 1, 2024, Danos acquired 58,867 shares of common stock related to a time-based restricted stock unit award (RSU).
• Also on August 1, 2024, Danos disposed of 126,216 shares of common stock.
• Following these transactions, Danos directly owns 185,083 shares of REGENXBIO common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The ESPP purchase is a positive sign, but the disposal of shares introduces uncertainty. Overall, it's a routine disclosure.

Positives

• The acquisition of shares through the ESPP demonstrates the executive's investment in the company's future.
• The vesting of restricted stock units aligns the executive's interests with the long-term performance of the company.

Negatives

• The disposal of 126,216 shares could be perceived negatively by investors, although the reason for disposal is not specified.

Risks

• Executive stock sales can sometimes be interpreted as a lack of confidence in the company's future prospects, potentially impacting investor sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's confidence in the company's prospects. ESPP participation is generally viewed positively, while large stock sales can raise concerns.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotechnology industry to align management's interests with shareholder value.
• Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also utilize similar equity-based compensation plans for their executives.
• The vesting schedules for RSUs, such as the one described in the document, are typical, often spanning several years to incentivize long-term commitment.

Stakeholder Impact

• Shareholders may react to the reported stock transactions, particularly the disposal of shares.
• Employees participating in the ESPP benefit from the opportunity to purchase company stock at a discounted price.

Key Dates